基于网络药理学策略预测并体外验证银杏内酯B的潜在适应证OA
Prediction and in vitro validation of potential indications for ginkgolide B based on network pharmacology strategies
目的:基于网络药理学方法预测银杏内酯B(GB)的潜在适应证,为其临床重定位提供参考.方法:汇总治疗靶点数据库、比较毒理基因组学数据库、蛋白质-小分子结合亲和力数据库等数据库获取的GB靶点,并对文献中已有报道的靶点进行二次核对,构建GB靶点集;整合全基因组关联分析与在线人类孟德尔遗传数据库的数据,建立标准化的疾病-基因数据集.基于人类蛋白质-蛋白质相互作用网络,采用网络邻近度计算药物靶点与疾病模块的拓扑距离,并通过标准化Z值与置换检验评估其显著性(Z<0,P<0.05).对候选疾病进行医学主题词表分类和网络可视化,并以Jaccard指数(J)分析候选疾病间基因集的相似性.通过体外实验验证GB对一氧化氮和促炎性细胞因子的抑制作用.结果:共筛选出12个GB潜在作用靶点,并构建了覆盖680种疾病的疾病-基因数据集.网络邻近度分析结果显示,GB与22种疾病存在显著关联,其中11种已有文献支持.疾病分类结果显示,GB潜在适应证主要集中在免疫介导炎症性疾病中,代表性疾病包括幼年特发性关节炎(Z=-3.10)和克罗恩病(Z=-3.05)等.药物-靶点-基因-疾病网络分析表明,GB可能通过丝裂原活化蛋白激酶1(MAPK1)等关键靶点参与多疾病的协同调控.Jaccard相似性最高的疾病对为幼年特发性关节炎-强直性脊柱炎(J=0.60).巨噬细胞体外实验结果表明,GB可抑制一氧化氮和促炎性细胞因子表达,提示其在免疫介导炎症性疾病中具有治疗潜力.结论:系统预测了GB的22种潜在适应证,并在体外实验中证实了GB治疗免疫介导炎症性疾病的潜力.
Objective:To predict potential indications for ginkgolide B(GB)based on network pharmacology strategies.Methods:GB targets were comprehensively identified by integrating data from the Therapeutic Target Database,the Comparative Toxicogenomics Database,and BindingDB,followed by further validation based on literature.A standardized disease-gene dataset was established by integrating data from the genome-wide association study and the Online Mendelian Inheritance in Man Database.The topological proximity between GB targets and disease modules within the human protein-protein interaction network was quantified using network proximity metrics,with statistical significance evaluated via Z-score and permutation testing(Z<0,P<0.05).Candidate diseases were classified according to MeSH terms,visualized through network mapping,and further characterized by gene set similarity based on the Jaccard index.Experiments in RAW 264.7 macrophages were conducted to validate the inhibitory effect of GB on nitric oxide and proinflammatory cytokines.Results:Twelve potential GB targets were identified,and a disease-gene dataset encompassing 680 diseases was established.Network proximity analysis revealed significant associations between GB and 22 diseases,of which 11 had prior literature support.Disease classification indicated that the predicted indications of GB were primarily enriched in immune-mediated inflammatory diseases,with notable examples including juvenile idiopathic arthritis(Z=-3.10)and Crohn disease(Z=-3.05).Network analysis suggested that GB may exert pleiotropic regulatory effects across multiple diseases via key targets such as MAPK1.The strongest gene set similarity was observed between juvenile idiopathic arthritis and ankylosing spondylitis(Jaccard index=0.60).In vitro experiments with macrophages demonstrated that GB suppresses the production of nitric oxide and proinflammatory cytokines,thereby supporting its potential as a therapeutic agent for immune-mediated inflammatory diseases.Conclusion:This study systematically predicted 22 potential indications for GB and confirmed its therapeutic potential for immune-mediated inflam-matory diseases through in vitro experiments.
张慧莹;范庆;张轶骅;刘梦晨;崔国祯
遵义医科大学珠海校区生物工程学院 贵州省市场监督管理局中药民族药质量控制与评价重点实验室,广东 珠海 519041遵义医科大学珠海校区基础教学部,广东 珠海 519041遵义医科大学珠海校区生物工程学院 贵州省市场监督管理局中药民族药质量控制与评价重点实验室,广东 珠海 519041遵义医科大学珠海校区生物工程学院 贵州省市场监督管理局中药民族药质量控制与评价重点实验室,广东 珠海 519041遵义医科大学珠海校区生物工程学院 贵州省市场监督管理局中药民族药质量控制与评价重点实验室,广东 珠海 519041
医药卫生
银杏内酯B适应证系统生物学网络药理学网络邻近度药物重定位免疫介导炎症性疾病
Ginkgolide BIndicationSystem biologyNetwork pharmacologyNetwork proximityDrug repositioningImmune-mediated inflammatory disease
《浙江大学学报(医学版)》 2026 (3)
267-277,11
国家自然科学基金(82160684)贵州省科技计划(黔科合基础-ZK[2022]一般587)广东省普通高校创新团队(2024KCXTD005)This study was supported by National Natural Science Foundation of China(82160684),Guizhou Provincial Science and Technology Plan(Qian Science Joint Basic-ZK[2022]General 587)and Innovation Team Project by Department of Education of Guangdong Province(2024KCXTD005)
评论